RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

Also Rusbrn, as RBlatch has noted on previous occasions, no one is leaving Cor.

OT, of interest buyout whispers about CVTX, up 15% today on large volume. I don't know if it is real or who the suiter(s) might be. A new class antianginal with favorable metabolic profile might fill the bill for BP (near term profitability with Ranexa and large growth potential for BP with good CV/Metabolic sales force).

Jerry, CVTX reminds me of AMLN, not just because they have similar 11 dollar SP, but because of their potential turn to profitability + double in 2009 and/or buyout.

CVTX and AMLN have fought the same FDA delaying headwinds as COR. It is a universal condition in biotechland.

It is probably worth a repeat mention that AMLN story includes a period when company pulled itself up from a 27 cent SP valuation in Oct 1998.